Advisory panel conflicts
This article was originally published in The Gray Sheet
Executive Summary
FDA could have done more to mitigate conflicts-of-interest among its advisory committee members by expanding outreach efforts to retired experts, academics and others, the Government Accountability Office concludes in a 1report released Oct. 9. FDA uses several methods to recruit panel members, but sometimes cannot find appropriate experts with no financial interests in the product or issue being discussed and must grant a waiver. Congress requested in 2005 that GAO investigate FDA's recruitment and waiver policies (2"The Gray Sheet" Sept. 26, 2005, p. 7). GAO reviewed 83 committee meetings convened by FDA's device, drug and biologics centers in 2004 and 2006, and interviewed consumer advocacy and trade groups, current and former FDA staff, and former panel members. About 16% of panel members received at least one conflict-of-interest determination, GAO found. In Aug. 28 comments, FDA questioned GAO's main criticism and highlighted four guidance documents on advisory panel policies, finalized Aug. 4, which are beyond the scope of the report (3"The Gray Sheet" Aug. 11, 2008, p. 3)
You may also be interested in...
With Five Guidances, FDA Overhauls Its Advisory Committee Policies
FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.